Moreover, in the late nineties several authors, by using immunohistochemical analysis of human prostate cancer specimens, described a down-regulation/loss of CD44 expression during human prostate cancer progression correlated with higher tumour grade and distant metastasis [39–41]. Here, CD44 is linked to prostate carcinoma.